Merck's Frazier Promoted To CEO To Drive Post-Schering Success
This article was originally published in The Tan Sheet
Executive Summary
Merck & Co. announced Nov. 30 it promoted current president Kenneth Frazier to CEO effective Jan. 1.
You may also be interested in...
Davis To Shepherd Merck & Co. Toward The Post-Keytruda Era, As Frazier Exits
Merck & Co.'s CFO Robert Davis will succeed Ken Frazier as CEO. Frazier was one of the architects of the Schering-Plough acquisition, which shaped the pharma for the next decade and delivered its top-selling drug, Keytruda.
In Brief
FDA clarifies pre-emption on OTC labeling
In Brief
FDA clarifies pre-emption on OTC labeling